Former Food and Drug Administration Commissioner Scott Gottlieb said the U.S. "may have a missed a window" to scale up production of coronavirus treatments, which "could have been an important bridge to a vaccine." On Tuesday, Gottlieb discussed the strategy of ratcheting up vaccine production even before federal approval to get a stockpile ready. He said the focus on vaccine development means less emphasis on a potential treatment known as monoclonal antibodies. The treatment, made of genetically engineered antibodies, is reportedly a promising method in fighting COVID-19, and two separate clinical trials are in progress. The speed has been focused on vaccines, though Gottlieb said the antibody treatment could serve as a "hedge in the event vaccines are delayed or don't work." Because of the slow progress, Gottlieb said, "we just don't have enough doses to realize that goal."

Scroll for 5 things you
need to know now